Free Trial
NASDAQ:CRVO

CervoMed Q1 2025 Earnings Report

CervoMed logo
$7.59 -0.57 (-6.99%)
Closing price 04:00 PM Eastern
Extended Trading
$7.60 +0.01 (+0.13%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

CervoMed Revenue Results

Actual Revenue
$1.92 million
Expected Revenue
$1.70 million
Beat/Miss
Beat by +$216.00 thousand
YoY Revenue Growth
N/A

CervoMed Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

CervoMed's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

CervoMed Earnings Headlines

Financial Review: CervoMed (CRVO) vs. Its Rivals
CervoMed (CRVO) & The Competition Head to Head Contrast
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
CervoMed (CRVO) & Its Peers Head-To-Head Comparison
See More CervoMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email.

About CervoMed

CervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

View CervoMed Profile

More Earnings Resources from MarketBeat